Anti-Infective Biotechs Face Partnering Gap  

Oleh:

Sheridan, Cormac

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 2 (Feb. 2005), page 155-156.
Topik: BIOTECHOLOGY; antiinfective; biotech; partnering gap

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Two more major pharmaceutical groups, aventia pharma and bayer announced recently that their strategies no longer include a focus on anti infectives leading, in the case of aventis, to the creation of a new spinout company. Novexel pharmaceutical withdrawal from antibiotic and antifungal drug development means that biotech companies, which are becoming increasingly responsible for the development pipeline, could find it difficult to find partners down the line. The two events that served to confirm the on going retreat of major pharmaceutical companies form the anti-infective drugs arena occured on siccessive days. On December 1, 2004, novexel was formally spun out of aventia pharma in paris, with a portfolio of five development projects including two undergoing phase...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali